NEXT GENERATION MAST CELL THERAPEUTICS
FROM NOVEL DISCOVERED BIOLOGY TO SUPERIOR THERAPEUTICS
Discovery of a novel mast cell target that is designed by nature to control and regulate the entire mast cell activity.
Key Advantages
Complete inhibition of mast cell activity independent of trigger of mast cell activation.
Selective inhibition only of activated mast cells that cause the disease symptoms without immuno-suppressive side effects.
Potentially disease-modifying over time („turning back the disease clock“)
Discovery of a novel mast cell target that is designed by nature to control and regulate the entire mast cell activity.
KEY ADVANTAGES
Complete inhibition of mast cell activity independent of trigger of mast cell activation.
Selective inhibition only of activated mast cells that cause the disease symptoms without immuno-suppressive side effects.
Potentially disease-modifying over time („turning back the disease clock“)
SUPERIOR THERAPEUTIC POTENTIAL AND SAFETY
Superior Therapeutic Efficacy: the novel discovered mast cell receptor enables MCS small molecules to control the entire mast cell activity independent of the activation trigger.
Multi-Symptom Treatment: the novel MCS treatment targets multiple disease symptoms and organs simultaneously (e.g. skin, gastro-intestinal, lung) reducing the need for multiple drugs and safety risks.
Disease-Modifying: potentially enabling a disease-modifying over time (“turning back the disease clock”).
Excellent Safety: selective inhibition of only activated mast cells that cause the problems resulting in no immune-suppressive side effects.
drug development and pipeline
LEAD PROGRAM
MCS11XXX with currently two lead program series (MCS111XX, MCS112XX) with unique accelerated development approach and high probability for clinical phase success.
MCS20XX targeting the accelerated reduction of accumulated mast cells, in specific only the activated mast cells causing the disease symptoms, in a controlled and safe manner.
MCS12XXX with adjusted binding modality for selected specific diseases.